SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that…
Biotechnology
US, Stamford [HQ]
Balance Sheet
6 Sheets · From 2023 to 2018Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Assets | 48.00 | 334.00 | 576.00 | 452.00 | 630.00 | 725.00 | |
|
Current
|
47.00 | 331.00 | 513.00 | 382.00 | 599.00 | 500.00 | |
| Cash And Equivalents | 45.00 | 327.00 | 147.00 | 103.00 | 67.00 | 176.00 | |
| Assets | 48.00 | 334.00 | 576.00 | 452.00 | 630.00 | 725.00 | |
| Accounts Receivables (AR) | - - | - - | - - | - - | - - | -5.00 | |
| Inventory | - - | - - | - - | - - | - - | 3.00 | |
| Short Term Investments | - - | - - | 361.00 | 269.00 | 524.00 | 303.00 | |
| Other Current Assets | 1.00 | 3.00 | 4.00 | 9.00 | 7.00 | 12.00 | |
|
Non Current
|
1.00 | 3.00 | 62.00 | 69.00 | 30.00 | 224.00 | |
| Property, Plant, Equipment (Net) | - - | - - | 3.00 | 4.00 | 18.00 | 24.00 | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | 11.00 | |
| Goodwill | - - | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | 57.00 | 62.00 | 8.00 | 185.00 | |
| Other Non Current Assets | 1.00 | 1.00 | 2.00 | 3.00 | 3.00 | 4.00 | |
| Liabilities | 67.00 | 12.00 | 19.00 | 30.00 | 72.00 | 99.00 | |
|
Current
|
3.00 | 11.00 | 17.00 | 29.00 | 51.00 | 78.00 | |
| Accounts Payable | - - | 1.00 | -1.00 | 2.00 | 4.00 | - - | |
| Short Term Debt | - - | - - | 1.00 | 1.00 | - - | 1.00 | |
| Deferred Revenue | - - | - - | - - | - - | 3.00 | 4.00 | |
| Tax Payable | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | 2.00 | 9.00 | 14.00 | 25.00 | 39.00 | 65.00 | |
|
Non Current
|
64.00 | - - | 1.00 | - - | 21.00 | 21.00 | |
| Long Term Debt | - - | - - | 1.00 | - - | 4.00 | 5.00 | |
| Leasing Obligations | - - | - - | 2.00 | 1.00 | 5.00 | 7.00 | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | -16.00 | -15.00 | |
| Other Non Current Liabilities | 64.00 | - - | - - | - - | 16.00 | 15.00 | |
| Equity | -19.00 | 322.00 | 557.00 | 422.00 | -569.00 | 626.00 | |
| Stockholders' Equity | -19.00 | 322.00 | 557.00 | 422.00 | -569.00 | 626.00 | |
| Retained Earnings | -22.00 | -73.00 | -118.00 | -292.00 | -569.00 | -895.00 | |
| Common Stock | - - | - - | - - | - - | - - | - - | |
| Preferred Stock | 2.00 | 334.00 | - - | - - | - - | - - | |
| Profit | -17.00 | -54.00 | -44.00 | -173.00 | -274.00 | -325.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | 1.00 | 395.00 | 675.00 | 715.00 | - - | 1,520.00 | |
| Loss Other Compr. Income | - - | -334.00 | - - | - - | - - | 1.00 |